Join the Head and Neck Cancer group to help and get support from people like you.
Head and Neck Cancer News (Page 2)
Related terms: Oral Cancer
Shifts in Trends Noted for Trachea, Bronchus, Lung Cancer Mortality
WEDNESDAY, Jan. 15, 2025 – Tobacco-associated trachea, bronchus, and lung (TBL) cancer mortality is declining, while ambient particulate matter (PM)-associated TBL cancer mortality is increasing,...
Surgeon General Highlights Link Between Alcohol and Cancer, Urges Warning Labels
MONDAY, Jan. 6, 2025 – In a new Advisory on Alcohol and Cancer Risk, Surgeon General Vivek Murthy connects alcohol consumption to increased cancer risk and calls for updated warning labels on...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
Risk for Head and Neck Cancer Lower for Coffee and Tea Drinkers
MONDAY, Dec. 23, 2024 – Coffee and tea drinkers have a reduced risk for head and neck cancer (HNC), according to research published online Dec. 23 in Cancer. Timothy Nguyen, M.P.H., from the...
Many Lack Knowledge of Link Between HPV and Oropharyngeal Cancer
TUESDAY, Dec. 17, 2024 – Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and did not improve from 2018 to 2020, according to...
Radiotherapy With Adjuvant Durvalumab No Benefit for Head, Neck Cancer
MONDAY, Dec. 9, 2024 – For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cisplatin, radiotherapy with adjuvant durvalumab does not...
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin
TUESDAY, Nov. 26, 2024 – Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial...
Fine Particulate Matter Linked to Increased Incidence of Head, Neck Cancer
THURSDAY, Nov. 21, 2024 – Exposure to air pollution in the form of particulate matter measuring less than 2.5 µm (PM2.5) is associated with an increased incidence of head and neck cancer, according ...
American Academy of Otolaryngology-Head and Neck Surgery, Sept. 28-Oct. 1
The annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery was held from Sept. 28 to Oct. 1 in Miami, drawing participants from around the world, including otolaryngologists,...
2023 Cisplatin Shortage Tied to Use of Alternatives for Head, Neck Cancer
TUESDAY, Oct. 1, 2024 – The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a...
Certain Oral Bacteria Tied to Risk for New Head, Neck Squamous Cell Cancer
WEDNESDAY, Oct. 2, 2024 – Certain oral bacteria are a risk factor for development of head and neck squamous cell cancer (HNSCC), according to a study published online Sept. 26 in JAMA Oncology. ...
Gum Disease Germs Could Help Trigger Cancer
THURSDAY, Sept. 26, 2024 – Bacteria that causes gum disease can also raise a person’s risk of head and neck cancers, a new study says. More than a dozen bacterial species have been linked to a c...
Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus Cancer
WEDNESDAY, Sept. 18, 2024 – Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b resectable nasal and paranasal sinus squamous...
FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) June 11, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...